While only about 20% of people would qualify for a formal diagnosis of a mental disorder, more than 60% express symptoms of those disorders – and those symptoms can lead to cognitive difficulties.
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International.
- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented